Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations.

Zhu Y, Curtis M, Snow-Lampart A, Yang H, Delaney W, Miller MD, Borroto-Esoda K.

J Clin Microbiol. 2007 Oct;45(10):3335-41. Epub 2007 Aug 8.

2.

Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.

Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N.

J Infect Dis. 2008 Oct 15;198(8):1150-8. doi: 10.1086/591941.

PMID:
18713056
3.
4.

A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.

Durantel D, Carrouée-Durantel S, Werle-Lapostolle B, Brunelle MN, Pichoud C, Trépo C, Zoulim F.

Hepatology. 2004 Oct;40(4):855-64.

PMID:
15382118
5.

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.

Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, Yu CF, Tenney DJ, Colonno RJ.

J Hepatol. 2008 Jun;48(6):895-902. doi: 10.1016/j.jhep.2007.12.024. Epub 2008 Feb 21.

PMID:
18362040
6.

HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays.

Zhu Y, Curtis M, Borroto-Esoda K.

J Virol Methods. 2011 May;173(2):340-6. doi: 10.1016/j.jviromet.2011.03.006. Epub 2011 Mar 17.

PMID:
21396961
7.

Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA.

Margeridon S, Carrouée-Durantel S, Chemin I, Barraud L, Zoulim F, Trépo C, Kay A.

Antimicrob Agents Chemother. 2008 Sep;52(9):3068-73. doi: 10.1128/AAC.01318-07. Epub 2008 Jul 7.

8.

High replicative full-length lamivudine-resistant hepatitis B virus isolated during acute exacerbations.

Zhang JM, Yao X, Wang YX, Liu F, Ma ZM, Weng XH, Wen YM.

J Med Virol. 2005 Oct;77(2):203-8.

PMID:
16121368
9.

Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.

Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.

J Med Virol. 2007 Nov;79(11):1664-70.

PMID:
17854034
10.

Analysis of hepatitis B virus quasispecies distribution in a Korean chronic patient based on the full genome sequences.

Kim H, Jee YM, Song BC, Hyun JW, Mun HS, Kim HJ, Oh EJ, Yoon JH, Kim YJ, Lee HS, Hwang ES, Cha CY, Kook YH, Kim BJ.

J Med Virol. 2007 Mar;79(3):212-9.

PMID:
17245716
11.

Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing.

Durantel D, Brunelle MN, Gros E, Carrouée-Durantel S, Pichoud C, Villet S, Trepo C, Zoulim F.

J Clin Virol. 2005 Dec;34 Suppl 1:S34-43. Review.

PMID:
16461221
13.

In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.

Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Dény P, Zoulim F.

Gastroenterology. 2009 Jan;136(1):168-176.e2. doi: 10.1053/j.gastro.2008.09.068. Epub 2008 Oct 7.

PMID:
18996386
14.

Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.

Pollicino T, Isgrò G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, Squadrito G, Di Marco V, Craxì A, Raimondo G.

Antivir Ther. 2009;14(5):649-54.

PMID:
19704167
15.

Quantification of lamivudine-resistant hepatitis B virus mutants by type-specific TaqMan minor groove binder probe assay in patients with chronic hepatitis B.

Yoshida S, Hige S, Yoshida M, Yamashita N, Fujisawa S, Sato K, Kitamura T, Nishimura M, Chuma M, Asaka M, Chiba H.

Ann Clin Biochem. 2008 Jan;45(Pt 1):59-64. doi: 10.1258/acb.2007.006219.

PMID:
18275675
16.

Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.

Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R, Buti M.

J Viral Hepat. 2007 Dec;14(12):835-40.

PMID:
18070286
17.

[Mutations of HBV polymerase gene sequence in lamivudine-resistant chronic hepatitis B patients].

Wang C, Sun J, Chen JJ, Wang ZH, Hou JL.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 May;28(5):729-30. Chinese.

PMID:
18504191
18.

Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers.

Kim JK, Lee HJ, Lee YJ, Chun JY, Lee IK, Lim YS, Suh DJ, Ko SY, Kim MH, Oh HB.

J Virol Methods. 2008 Apr;149(1):76-84. doi: 10.1016/j.jviromet.2008.01.003. Epub 2008 Mar 4.

PMID:
18291537
19.

Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.

Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM.

Int J Infect Dis. 2008 Jan;12(1):83-7. Epub 2007 Aug 14.

20.

Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.

Iacomi F, Vincenti D, Vairo F, Solmone M, Mariano A, Piselli P, Puro V, Capobianchi MR, Antonucci G.

J Med Virol. 2009 Jul;81(7):1151-6. doi: 10.1002/jmv.21505.

PMID:
19475624

Supplemental Content

Support Center